Sabon Maganin Kiba

Written by edita

Sciwind Biosciences Co., Ltd., wani kamfani ne na likitanci na asibiti wanda ya mayar da hankali kan ganowa da haɓaka sabbin hanyoyin kwantar da hankali don magance cututtukan rayuwa, a yau ya sanar da ƙaddamar da maganin marasa lafiya a cikin gwajin asibiti na Phase 2b na XW003 a cikin marasa lafiya da kiba.

Print Friendly, PDF & Email

XW003 labari ne, mai dorewa na glucagon-kamar peptide-1 (GLP-1) analog wanda aka haɓaka a Sciwind Biosciences. An nuna cewa yana da aminci kuma an jure shi sosai, da kuma haifar da raguwar nauyin dogara ga kashi a farkon gwaji na asibiti.

Cibiyar da yawa, bazuwar, alamar buɗaɗɗen, gwajin gwaji na Mataki na 2b mai sarrafa aiki don kimanta gudanarwar subcutaneous na XW003 sau ɗaya kowane mako a cikin kusan marasa lafiya 200 masu kiba. Masu shiga cikin gwajin, wanda ake gudanarwa a Ostiraliya da New Zealand, za a bi da su tare da magungunan nazarin har zuwa makonni 26, sannan kuma za a yi amfani da su na tsawon makonni 5 ba tare da kulawa ba. Manufar binciken ita ce kimanta aminci, juriya, da ingancin jiyya na XW003 a cikin marasa lafiya masu kiba. Ana sa ran bayanan da suka fi girma a cikin rabin na biyu na 2022. Bugu da ƙari, a matsayin wani ɓangare na shirin ci gaba na XW003 gabaɗaya, ana kuma gudanar da wani gwaji na dabam a cikin marasa lafiya na kasar Sin masu fama da kiba.

"Mun yi matukar farin ciki da ci gaba da ci gaba da sauri na XW003 ta hanyar ci gaban asibiti. Ƙaddamar da allurar rigakafi a cikin wannan cibiyar da yawa, nazarin kasa da kasa don maganin kiba wani muhimmin ci gaba ne ga kamfanin kuma babban shaida ga sadaukarwar ƙungiyarmu da iyawarmu, "in ji Dokta Hai Pan, wanda ya kafa kuma Shugaba na Sciwind. "Mun himmatu don ci gaba da haɓaka XW003, da kuma sauran masu neman magani a bututun Sciwind, don magance cututtukan da suka haɗa da kiba, ciwon sukari, da NASH."

Print Friendly, PDF & Email

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment